Timolol maleate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1978
- First approval year
- 1978
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Timolol maleate
- Molecular weight
- 432.5
- Structure (SMILES)
- CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O
- blocadren
- Blocadren
- istalol
- Istalol
- timolol maleate
- Timolol maleate
- timolol maleate component of combigan
- Timolol maleate component of combigan
- timolol maleate component of cosopt
- Timolol maleate component of cosopt
- timolol maleate component of duotrav
- Timolol maleate component of duotrav
- timolol maleate component of ganfort
- Timolol maleate component of ganfort
- timolol maleate component of xalacom
- Timolol maleate component of xalacom
- timoptic
- Timoptic
- timoptic in ocudose
- Timoptic in ocudose
- timoptic xe
- Timoptic xe
- Timoptic-xe
- (-)-1-(TERT-BUTYLAMINO)-3-((4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)OXY)-2-PROPANOL MALEATE (1:1) (SALT)
- 1 tert butylamino 3 4 morpholino 1 2 5 thiadiazol 3 yl oxy 2 propanol maleate 1 1 salt
- 2 propanol 1 1 1 dimethylethyl amino 3 4 4 morpholinyl 1 2 5 thiadiazol 3 yl oxy s z 2 butenedioate 1 1 salt
- 2-PROPANOL, 1-((1,1-DIMETHYLETHYL)AMINO)-3-((4-(4-MORPHOLINYL)-1,2,5-THIADIAZOL-3-YL)OXY)-, (S)-, (Z)-2-BUTENEDIOATE (1:1) (SALT)
- aquanil
- Aquanil
- combigan component timolol maleate
- COMBIGAN COMPONENT TIMOLOL MALEATE
- cosopt component timolol maleate
- COSOPT COMPONENT TIMOLOL MALEATE
- duotrav component timolol maleate
- DUOTRAV COMPONENT TIMOLOL MALEATE
- ganfort component timolol maleate
- GANFORT COMPONENT TIMOLOL MALEATE
- nsc 757351
- NSC-757351
- ophtamolol
- Ophtamolol
- Timolol (as maleate)
- timolol 0 5 ophthalmic solution timoptic
- Timolol 0.5% Ophthalmic Solution (Timoptic)
- timolol as maleate
- timolol hydrogen maleate salt
- Timolol hydrogen maleate salt
- TIMOLOL HYDROGEN MALEATE SALT [MI]
And 38 more, listed on the interactive page.
- CAS registry numbers
- 26921-17-5
- ChEMBL ID
- CHEMBL1200870
- InChIKey
- WLRMANUAADYWEA-NWASOUNVSA-N
- FDA ingredient codes (UNII)
- P8Y54F701R
- Applicant
- BAUSCH AND LOMB INC
- Approval date
- 17 Aug 1978
- Application number
- NDA018086
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Drug name stem
- -olol
Administration routes
- Oral
- topical
- Mechanism
- Beta-1 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-1 adrenergic receptor
- Protein identifier
- P08588
- Mechanism
- Beta-2 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-2 adrenergic receptor
- Protein identifier
- P07550
- Mechanism
- Beta-1 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
- Action type
- Antagonist
- Target
- Beta-2 adrenergic receptor
- Condition
- Hypertension, Portal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000666
- Subject identifier
- D006975
- Condition
- Glaucoma, Open-Angle
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004190
- Subject identifier
- D005902
- Condition
- Hemangioma
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000635
- Subject identifier
- D006391
- Condition
- Optic Neuropathy, Ischemic
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000809
- Subject identifier
- D018917
- Condition
- Corneal Edema
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000879
- Subject identifier
- D015715
- Condition
- Low Tension Glaucoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001022
- Subject identifier
- D057066
- Condition
- Ocular Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001069
- Subject identifier
- D009798
- Condition
- Glaucoma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005041
- Subject identifier
- D005901
- Condition identifier
- EFO_0004190
- Condition identifier
- EFO_1000635
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000809
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000879
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001022
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001069
- Condition identifier
- HP_0001009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002407
- Condition identifier
- MONDO_0002407
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005041
- Condition identifier
- MONDO_0005041
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005338
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005898
- Condition identifier
- MONDO_0006500
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006712
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006837
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006875
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0019180
- Condition identifier
- MONDO_0019180
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0024291
- Highest recorded phase
- 1
- Condition identifier
- Orphanet_98671
- Highest recorded phase
- 1
- Event
- abnormal sensation in eye
- Reports
- 11
- Reporting signal score
- 26.3077
- Event
- anaemia
- Reports
- 2
- Reporting signal score
- 26.4884
- Event
- anterior chamber disorder
- Reports
- 8
- Reporting signal score
- 31.7936
- Event
- blepharitis
- Reports
- 19
- Reporting signal score
- 52.1433
- Event
- blindness
- Reports
- 30
- Reporting signal score
- 32.7553
- Event
- bradycardia
- Reports
- 104
- Reporting signal score
- 130.088
- Event
- cataract
- Reports
- 37
- Reporting signal score
- 38.8159
- Event
- choroidal detachment
- Reports
- 13
- Reporting signal score
- 45.7763
- Event
- choroidal effusion
- Reports
- 9
- Reporting signal score
- 26.3125
- Event
- conjunctivitis
- Reports
- 25
- Reporting signal score
- 34.1482
- Event
- conjunctivitis allergic
- Reports
- 10
- Reporting signal score
- 29.7475
- Event
- corneal deposits
- Reports
- 24
- Reporting signal score
- 97.9111
- Event
- corneal oedema
- Reports
- 25
- Reporting signal score
- 72.7574
- Event
- diarrhoea
- Reports
- 10
- Reporting signal score
- 50.3491
- Event
- dry eye
- Reports
- 33
- Reporting signal score
- 44.3187
- Event
- erythema of eyelid
- Reports
- 18
- Reporting signal score
- 46.4502
- Event
- eye burns
- Reports
- 10
- Reporting signal score
- 40.3283
- Event
- eye discharge
- Reports
- 42
- Reporting signal score
- 122.112
- Event
- eye disorder
- Reports
- 31
- Reporting signal score
- 46.0135
- Event
- eye inflammation
- Reports
- 17
- Reporting signal score
- 32.9378
- Event
- eye irritation
- Reports
- 230
- Reporting signal score
- 754.476
- Event
- eye pain
- Reports
- 138
- Reporting signal score
- 353.682
- Event
- eye pruritus
- Reports
- 82
- Reporting signal score
- 211.129
- Event
- eye swelling
- Reports
- 58
- Reporting signal score
- 107.751
- Event
- eyelid disorder
- Reports
- 12
- Reporting signal score
- 34.8227
And 32 more, listed on the interactive page.
- NCT00006398
- NCT00108017
- NCT00293787
- NCT00311389
- NCT00753168
- NCT01279083
- NCT00449956
- NCT00519753
- NCT00811850
- NCT01336569
- NCT01514721
- NCT01514734
- NCT01518244
- NCT01845038
- NCT02697318
- NCT02852057
- NCT00273455
- NCT02754596
- NCT00800423
- NCT01607671
- NCT01685398
- NCT02145884
- NCT02913612
- NCT04857827
- Dose
- 1 drop
- Route
- Topical
- How often
- Twice daily
Conditions of use
- Instill at least 5 minutes apart if using multiple drops
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 79.74
- Calculated partition coefficient (ALogP)
- 0.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 29
- Molecular formula
- C17H28N4O7S
- Monoisotopic mass
- 432.16787042
- Natural product
- No
- 0023-9211
- 0378-0221
- 0781-7186
- 0832-1425
- 14445-405
- 16571-223
- 16571-224
- 16571-225
- 24208-004
- 24208-486
- 24208-498
- 24208-499
- 24208-812
- 24208-813
- 24208-814
- 24208-816
- 25021-008
- 25021-009
- 42571-147
- 42571-382
- 42571-398
- 42571-403
- 42571-404
- 43598-747
- 43598-748
And 89 more, listed on the interactive page.
- Recorded assays
- 1,831
- Active assays
- 6
- Confirmatory
- Screening
- Adrenergic beta-Antagonists
- Anti-Arrhythmia Agents
- Antihypertensive Agents
Related records
Trials (232)
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice
- 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
- 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination
- 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG
- A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
- A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
- A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
- A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
- A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
- A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
- A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
Approved for (3)
In development for (5)
- Anterior ischemic optic neuropathy Phase 1
- Corneal edema Phase 3
- Hemangioma Phase 3
- Low tension glaucoma Phase 2
- Portal hypertension Phase 3
Other linked conditions (2)
- Capillary hemangioma
- Hereditary hemorrhagic telangiectasia